---
title: "ACP licenses its guidelines to OpenEvidence for an undisclosed price"
description: "The largest US medical society's guidance moves into a free, ad-funded AI valued at $15 billion, and neither side named the fee. For listed readers, the test is Wolters Kluwer's UpToDate renewals at February 2027 results."
publisher: "The Inference"
section: "Health"
published: 2026-11-10T17:04:09.086Z
modified: 2026-11-10T17:04:09.086Z
canonical: https://theinference.org/article/acp-licenses-its-guidelines-to-openevidence-for-an-undisclosed-price
language: en
keywords: "OpenEvidence, Wolters Kluwer, Clinical Guidelines, Medical Publishing, AI In Medicine"
---

# ACP licenses its guidelines to OpenEvidence for an undisclosed price

> The largest US medical society's guidance moves into a free, ad-funded AI valued at $15 billion, and neither side named the fee. For listed readers, the test is Wolters Kluwer's UpToDate renewals at February 2027 results.

The American College of Physicians, the largest medical specialty organization in the United States with 163,000 members, [agreed on November 9, 2026, to license its clinical guidance and the peer-reviewed content of its journal, Annals of Internal Medicine](https://www.prnewswire.com/news-releases/acp-and-openevidence-collaborate-to-enhance-physician-access-to-trusted-clinical-guidance-302929717.html), into [OpenEvidence](https://theinference.org/markets/companies/openevidence), an AI platform doctors consult at the point of care [1][2]. Neither side disclosed the fee, the term or the renewal structure [1][2]. Internal medicine is already the platform's largest specialty [1], so this is less a new door than a keystone.

## The bill under the $15 billion mark

OpenEvidence charges verified clinicians nothing; pharmaceutical and device advertisers pay [3]. Investors re-rated that model from $1 billion in February 2025 to $15 billion in September 2026, when [a $250 million round led by Byers Capital and Andreessen Horowitz closed](https://aimagazine.com/news/openevidence-doctors-ai-search-engine-valued-at-us-15bn), about 50 times the roughly $300 million of annualized revenue Sacra estimated for July 2026 [3].

*Chart: **Three rounds priced OpenEvidence from $1 billion to $15 billion in 19 months** Line chart of OpenEvidence post-money valuations rising from $1 billion in February 2025 to $12 billion in January 2026 and $15 billion in September 2026.*

*Post-money valuation after each funding round, US dollars. February 2025 Series A at $1 billion; January 2026 Series D at $12 billion; September 2026 round at $15 billion. Source: AI Magazine, November 4, 2026. [3]*

The platform now licenses NEJM Group, JAMA Network, Wiley, Cochrane, the American College of Cardiology, the American Diabetes Association, NCCN and the American Urological Association, and not one license price is public [3]. ACP is the ninth named content partner, and its members write the guidance at the center of the largest specialty [3][1]. Every content renewal is now a negotiation between the platform and the authorities it answers with.

## Treatment questions, graded by the same societies

The license lands where liability concentrates. A federally funded JAMA analysis of 271 million OpenEvidence queries by Harvard and Brigham and Women's Hospital researchers found [treatment and management questions outnumber diagnostic ones, 33.1% against 13.9%](https://dhinsights.org/news/study-of-271-million-openevidence-queries-shows-clinicians-use-ai-as-a-colleague-not-a-textbook-raising-evaluation-questions), and disclosed that several of its authors are OpenEvidence employees [4]. The same package reported that only 5% of 519 clinical AI studies used real patient data [4].

OpenEvidence's answer is its own: it said [a study presented at the American College of Rheumatology's plenary](https://x.com/OpenEvidence/status/2119522487658549327) ranked it first of five platforms on 60 scenarios built from ACR and EULAR guidelines, at 91.2% agreement [5]. Societies' guidelines now both ground the answers and grade the tools; the ACP deal adds the paying version of that relationship.

## February 2027 is the reading that matters

The listed exposure is [Wolters Kluwer](https://theinference.org/markets/companies/wolters-kluwer), the Amsterdam-traded owner of UpToDate, the subscription clinical reference hospitals buy; hospitals take most of UpToDate's revenue, which makes switching harder for them than for individual doctors [6]. It is embedding UpToDate in Epic, Suki and [Doximity](https://theinference.org/markets/companies/doximity) and says 95% of its large US customers already use UpToDate Expert AI, supplied free so renewal prices can rise later [6]. Clinical Solutions, the unit behind UpToDate, [grew 6% in the first nine months against 7% a year earlier](https://markets.businessinsider.com/news/stocks/wolters-kluwer-2026-nine-month-trading-update-1036713229), with recurring revenue at 85% of group sales [6].

*Chart: **Clinical Solutions growth slipped a point while group growth held** Column chart of organic revenue growth: Wolters Kluwer Clinical Solutions grew 7% in the first nine months of 2025 and 6% in the first nine months of 2026, while group organic growth held at 6% in the first nine months of 2026.*

*Organic revenue growth, percent, first nine months of each year as reported. Source: VEB, November 9, 2026; Wolters Kluwer 2026 Nine-Month Trading Update, November 4, 2026. [6][8]*

The shares sat at €87.54 on November 10, still working off a year of AI-fear losses [6][7]. [The Inference covered the $15 billion round and its hospital bets in October](https://theinference.org/article/15-billion-for-a-free-tool-openevidence-bets-its-doctors-reach-on-hospitals-and-cancer-trials); the content bill was the open number then, and ACP has just added to it. In February 2027 the annual figures will show whether UpToDate renewals carry price rises against a free rival now holding ACP's guidelines [6][7].

## Takeaway

ACP's guidelines move into OpenEvidence for an undisclosed fee, and the first place the price of free shows up for listed readers is Wolters Kluwer's UpToDate renewals at February 2027 results.

## Sources

1. [PRNewswire, ACP and OpenEvidence collaborate to enhance physician access to trusted clinical guidance, 9 November 2026](https://www.prnewswire.com/news-releases/acp-and-openevidence-collaborate-to-enhance-physician-access-to-trusted-clinical-guidance-302929717.html)
2. [ACP Online newsroom, ACP and OpenEvidence collaborate to enhance physician access to trusted clinical guidance, November 2026](https://www.acponline.org/acp-newsroom/acp-and-openevidence-collaborate-to-enhance-physician-access-to-trusted-clinical-guidance)
3. [AI Magazine, OpenEvidence: Doctors' AI Search Engine Valued at US$15bn, 4 November 2026](https://aimagazine.com/news/openevidence-doctors-ai-search-engine-valued-at-us-15bn)
4. [Digital Health Insights, Study of 271 million OpenEvidence queries shows clinicians use AI as a colleague, not a textbook, 4 November 2026](https://dhinsights.org/news/study-of-271-million-openevidence-queries-shows-clinicians-use-ai-as-a-colleague-not-a-textbook-raising-evaluation-questions)
5. [OpenEvidence on X, post on the ACR plenary guideline study, 8 November 2026](https://x.com/OpenEvidence/status/2119522487658549327)
6. [VEB (Vereniging van Effectenbezitters), Wolters Kluwer ziet AI-angst op de beurs langzaam wegebben, 9 November 2026](https://www.veb.net/artikel/10619/wolters-kluwer-ziet-ai-angst-op-de-beurs-langzaam-wegebben)
7. [Wolters Kluwer, Investors page, share price €87.54 updated 10 November 2026](https://www.wolterskluwer.com/en/investors)
8. [Markets Insider (GlobeNewswire), Wolters Kluwer 2026 Nine-Month Trading Update, 4 November 2026](https://markets.businessinsider.com/news/stocks/wolters-kluwer-2026-nine-month-trading-update-1036713229)


---

ACP licenses its guidelines to OpenEvidence for an undisclosed price — The Inference. Canonical: https://theinference.org/article/acp-licenses-its-guidelines-to-openevidence-for-an-undisclosed-price